Surrozen, Inc. (SRZN) - Q2 2026 Filing Summary
Business Context and Reporting Period
This summary covers Surrozen, Inc.'s Form 10-Q for the quarterly period ended June 30, 2026. Surrozen is a biotechnology company focused on discovering and developing product candidates to selectively modulate the Wnt pathway, with a strategic focus on ophthalmology. The company operates as a single segment and is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Total Revenue | $5.0 million | $10.0 million | $2.0 million |
| Net Income (Loss) | $50.2 million | $(77.3) million | $12.8 million |
| Operating Loss | $(10.4) million | $(20.8) million | $(18.6) million |
| Cash and Cash Equivalents | $102.0 million | $102.0 million | $90.4 million |
| Accumulated Deficit | $(604.6) million | $(604.6) million | $(527.3) million |
| Tranche Liability | $196.3 million | $196.3 million | $158.7 million |
| Warrant Liabilities | $124.7 million | $124.7 million | $112.5 million |
Note: Q2 2026 net income was driven by non-cash gains of $59.6 million related to changes in the fair value of tranche and warrant liabilities. YTD 2026 net loss included a $37.6 million non-cash loss on the change in fair value of the tranche liability.
Material Changes vs. Prior Period
- Revenue Composition: Revenue in Q2 2026 consisted entirely of $5.0 million in collaboration and license revenue from Boehringer Ingelheim, triggered by a development milestone. This contrasts with Q2 2025, which had no collaboration revenue but $1.0 million in related-party research service revenue (now terminated).
- Operating Expenses: Total operating expenses increased 54% in Q2 2026 ($15.4 million) compared to Q2 2025 ($10.0 million). This was driven by a 40% increase in R&D expenses (due to manufacturing and lab costs for SZN-8141) and a 74% increase in G&A expenses (due to stock-based compensation and IP defense costs).
- Non-Cash Volatility: The company reported a significant swing in non-cash fair value adjustments. While Q2 2026 saw a $39.2 million gain on the tranche liability, the YTD 2026 period recorded a $37.6 million loss on the same item, contrasting with a $47.9 million gain in YTD 2025.
- Liquidity: Cash balances increased by $12.7 million YTD 2026, primarily due to financing activities including $26.9 million from the At-The-Market (ATM) program and warrant exercises, offset by $19.9 million in operating cash burn.
Guidance, Outlook, and Risks
- Capital Resources: Management believes existing cash of $102.0 million is sufficient to fund operations for at least the next 12 months. However, the company anticipates needing additional capital to advance clinical trials and may raise funds through equity offerings or collaborations.
- 2025 PIPE Second Tranche: A contingent second tranche of the 2025 Private Placement (PIPE) could provide approximately $95.1 million in gross proceeds if the FDA clears the Investigational New Drug (IND) application for SZN-8141 by October 31, 2026.
- Collaboration Dispute: Boehringer Ingelheim has asserted a contractual remedy to reduce future milestone and royalty payments under their Collaboration and License Agreement (CLA). Surrozen believes this interpretation is without merit. The company recognized $5.0 million for a June 2026 milestone, reflecting a 50% reduction from the full $10.0 million amount, pending resolution.
- Key Risks: Significant risks include the failure of product candidates to achieve regulatory approval, the high cost of clinical development, potential dilution from future financing, and the outcome of the contractual dispute with Boehringer Ingelheim.
Investor Verification Checklist
- Boehringer Ingelheim Dispute: Verify the status of the contractual disagreement regarding milestone payments and the potential impact on future revenue recognition.
- 2025 PIPE Milestone: Monitor the timeline for the SZN-8141 IND clearance (targeted for Q3 2026) which triggers the $95.1 million second tranche funding.
- Non-Cash Adjustments: Scrutinize the volatility in fair value measurements of tranche and warrant liabilities, which significantly distort net income/loss figures.
- Cash Burn Rate: Assess the sustainability of the current cash position given the $19.9 million operating cash burn in the first half of 2026 and the lack of product sales revenue.
- Stock-Based Compensation: Review the increasing trend in stock-based compensation expenses ($5.0 million YTD 2026 vs. $1.8 million YTD 2025) and its impact on future dilution.